GLP1R and type 2 diabetes mellitus: Comorbidities associatedwith obesity and type 2 diabetes (T2D)continue to be great health challenges with the global populationseeing rising child and adult obesity and diabetes rates.1,2 Pharmacotherapies targeting gut peptide signaling pathways, suchas glucagon-like peptide-1 receptor agonists (GLP-1RAs), arguablyshow the greatest promise for the treatment of comorbidities associatedwith obesity and T2D.